Nevertheless, our results support making PAK2 a focus for clinical drug development and indicate that TP53 mutation status and PAK2 copy gains within the 3q amplicon should be jointly considered in future studies evaluating efficacy of PAK2 inhibition in HPV(−) HNSCC. This evidence concerns the gene PAK2 and head and neck squamous cell carcinoma.